Summit agrees to $2 billion AstraZeneca equity investment

What happened

Summit Therapeutics Inc. (NASDAQ: SMMT) said AstraZeneca will invest $2.0 billion in convertible preferred shares. The agreement values the conversion at a common-stock equivalent price of $18.36, which the filing says is a premium over today's closing trading price. The securities purchase agreement says AstraZeneca will buy approximately 108,955 preferred shares at a 1:1,000 conversion ratio.

The release also says Summit entered a clinical collaboration with AstraZeneca focused on ivonescimab and sonesitatug vedotin. Summit said it also plans to evaluate ivonescimab with an additional set of AstraZeneca cancer medicines, including other antibody drug conjugates.

Key numbers

Metric	Latest	Change	Source
AstraZeneca investment	$2.0 billion		SEC 8-K Exhibit 99.1
Common stock price equivalent	$18.36		SEC 8-K Exhibit 99.1
Preferred shares to be purchased	approximately 108,955 shares		SEC 8-K Exhibit 10.1
Per Share Price	$18,356.14		SEC 8-K Exhibit 10.1

Read more: Summit Therapeutics (SMMT) stock analysis and investment case

Why it matters

OptimistFi's case is that Summit Therapeutics is a high-upside, high-binary-risk oncology platform whose stock works only if ivonescimab proves clinically and commercially strong enough before cash needs force punitive financing. This financing eases that pressure and gives investors a new baseline for judging execution. The collaboration covers studies in certain gastrointestinal cancer settings and is intended to start imminently.

Under that agreement, each company will contribute its own compound and the parties will jointly contribute to study costs. Each company will keep development and commercial rights to its own molecule. Summit and AstraZeneca also executed a non-binding memorandum of understanding to explore ivonescimab with multiple AstraZeneca cancer medicines, including other antibody drug conjugates. The filing says that broader plan is mutually non-exclusive and carries no additional financial considerations tied to milestones, royalties, revenue-sharing or profit-sharing.

AstraZeneca reported positive results from CLARITY-Gastric01 for sone-ve, and Summit said those results will be presented at the European Society for Medical Oncology Congress 2026 in a Presidential Symposium alongside HARMONi-GI1. The caveat is that the memorandum is non-binding, and the financing still depends on customary closing conditions.

Related: Summit Therapeutics Inc. (NASDAQ: SMMT) Adds Detail to Lung-Cancer Survival Data

What's next

Closing is expected by the end of this week. After closing, Summit said it will file a registration statement with the SEC to register resale of the common stock underlying the preferred shares. If closing misses the expected timing, the filing says the wired funds must be returned within one business day after the expected closing date. A completed closing would lock in the $2.0 billion investment, while a missed closing would leave that financing unrealized.

More from OptimistFi